Substance use and poisoning - Articles - Page 7

Illustration of head composed of alcoholic beverage glasses

Substance Use & Poisoning

NIH grant to support early development of Amygdala Neurosciences’ ALDH2 inhibitor for AUD

Aug. 2, 2023

Amygdala Neurosciences Inc. has been awarded a $2.0 million NIH grant to support IND-enabling and early-stage development of its selective, reversible, orally bioavailable aldehyde dehydrogenase 2 (ALDH2) inhibitor ANS-858 to treat alcohol use disorder (AUD).

Various pills and powders in small plastic ziplock bags

Substance Use & Poisoning

Cessation receives IND clearance for first-in-human study of CSX-1004 for prevention of fentanyl overdose

July 27, 2023

Cessation Therapeutics Inc. has obtained IND clearance from the FDA to initiate a first-in-human trial of CSX-1004 for the prevention of fentanyl overdose. The trial in healthy volunteers is expected to begin next month.

Substance Use & Poisoning

ADX-106772 reduces oxycodone taking and seeking in rats

July 25, 2023

Researchers from Addex Therapeutics Ltd. have published preclinical data for the novel positive allosteric modulator of the metabotropic glutamate mGlu2 receptor, ADX-106772, being developed for the treatment of opioid use disorder (OUD).

Substance Use & Poisoning

Adamis announces NIAAA grant to support development of bifunctional molecules for alcohol use disorder

June 27, 2023

Adamis Pharmaceuticals Corp.’s wholly owned subsidiary DMK Pharmaceuticals Corp. has been awarded a grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the National Institutes of Health (NIH) to support the development of a novel bifunctional small molecule for the treatment of alcohol use disorder.

Neurology/Psychiatric

Psilera nominates non-hallucinogenic psilocybin derivative as lead clinical candidate

May 26, 2023

Psilera Inc. has selected a novel, non-hallucinogenic psilocybin derivative, PSIL-006...

Substance Use & Poisoning

TLR7/8 agonist enhances efficacy of M-sKLH vaccine for opioid use disorder

May 24, 2023

At the recent ASPET meeting, University of Minnesota and University of Montana researchers presented data from studies to determine the ability of the Toll-like receptor 7 (TLR7) and TLR8 agonist INI-4001 to enhance the efficacy of the heroin vaccine M-sKLH for the treatment of opioid use disorder.

Substance Use & Poisoning

Onquality receives IND clearance for OQL-036 for capecitabine-induced hand-foot syndrome

May 2, 2023

Onquality Pharmaceuticals LLC has received FDA clearance of its IND application for OQL-036, a potential prophylactic treatment for capecitabine-induced hand-foot syndrome (HFS).

Substance Use & Poisoning

State University of New Jersey presents new GABA-A receptor PAMs for alcoholism

May 2, 2023

State University of New Jersey (Rutgers) has divulged flavonoids acting as GABA-A receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of alcoholism.

Substance Use & Poisoning

Discovery and preclinical evaluation of dopamine D4 receptor-selective ligand CAB-01-019

April 14, 2023

Researchers from High Point University recently reported the discovery and preclinical evaluation of a novel class of highly selective dopamine D4 receptor-selective ligands as potential therapeutic candidates for substance use disorders.

Substance Use & Poisoning

New opioid receptor modulator has the noncompetitive advantage

March 29, 2023

By Anette Breindl

Researchers at Indiana University Bloomington have developed allosteric modulators of the opioid receptor that were superior to the opioid antidote naloxone at blocking the effects of fentanyl in vitro. They presented their work in a session on “Progress towards more efficacious medicine: Antibiotics and antidotes” at the 2023 spring meeting of the American Chemical Society (ACS).

Substance use and poisoning, BioWorld Science
RSS

NIH grant to support early development of Amygdala Neurosciences’ ALDH2 inhibitor for AUD

Cessation receives IND clearance for first-in-human study of CSX-1004 for prevention of fentanyl overdose

ADX-106772 reduces oxycodone taking and seeking in rats

Adamis announces NIAAA grant to support development of bifunctional molecules for alcohol use disorder

Psilera nominates non-hallucinogenic psilocybin derivative as lead clinical candidate

TLR7/8 agonist enhances efficacy of M-sKLH vaccine for opioid use disorder

Onquality receives IND clearance for OQL-036 for capecitabine-induced hand-foot syndrome

State University of New Jersey presents new GABA-A receptor PAMs for alcoholism

Discovery and preclinical evaluation of dopamine D4 receptor-selective ligand CAB-01-019

New opioid receptor modulator has the noncompetitive advantage

Today's news in brief

Ethyreal launches to treat the underlying cause of Graves’, TED

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

Microbiota modulates the antidepressant effects of GLP-1 analogues

Substance use and poisoning, BioWorld Science RSS

Substance use and poisoning, BioWorld Science
RSS